Skip to main content
. 2015 Jan;21(1):22–34. doi: 10.1177/1352458514549398

Figure 1.

Figure 1.

Trial design of CARE-MS I7 and CARE-MS II.8

In CARE-MS II, randomization into a third treatment arm (alemtuzumab 24 mg) was discontinued early and deemed exploratory for statistical purposes. CARE-MS: Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis IFNβ-1a: interferon beta-1a; IV: intravenous; SC: subcutaneous.